Medical Pharmacology: Chapter: 26 — Renal Pharmacology -- Module: 5 — Fluid, Acid-Base, and Electrolyte Emergencies

Chapter: 26 — Renal Pharmacology — Module: 5 — Fluid, Acid-Base, and Electrolyte Emergencies
Tier: T3 (Clinical Vignette)

1. An 80-year-old man with chronic atrial fibrillation managed with digoxin 0.125 mg daily and stage 4 CKD is brought to the emergency department after two days of poor oral intake. His serum potassium is 7.0 mEq/L. ECG shows peaked T waves, a PR interval of 240 ms, and widened QRS (ventricular depolarization complex) complexes. His serum digoxin level is 1.1 ng/mL (therapeutic). The emergency physician recognizes that first-line membrane stabilization is needed but is concerned about the digoxin interaction. Which of the following represents the most appropriate immediate management sequence for this patient?

A) Withhold calcium gluconate entirely given the digoxin interaction; proceed directly to insulin 10 units IV with dextrose 50% as the first intervention, then arrange hemodialysis for definitive potassium elimination
B) Administer sodium bicarbonate 50 mEq IV as the first intervention to alkalinize plasma and shift potassium intracellularly, avoiding any calcium-containing agent in a digoxin-treated patient; follow with insulin-dextrose and loop diuretic
C) Administer calcium gluconate 1 g IV as a slow infusion over 20–30 minutes rather than a rapid bolus, accepting the modest digoxin interaction risk because the immediate threat of ventricular fibrillation from severe hyperkalemia exceeds the interaction risk; follow with insulin 10 units IV plus dextrose 50% for redistribution, then initiate sodium zirconium cyclosilicate (SZC) for definitive potassium elimination given adequate residual urine output
D) Administer calcium chloride 1 g via the existing peripheral IV access as the preferred formulation in digoxin-treated patients because calcium chloride has a lower pH than calcium gluconate and is less likely to potentiate digoxin-mediated intracellular calcium loading
E) Administer calcium gluconate 2 g IV by rapid bolus to achieve the fastest possible membrane stabilization, then proceed with albuterol nebulization 20 mg as the sole redistribution agent, avoiding insulin entirely because hypoglycemia in a digoxin-treated patient can precipitate arrhythmias

ANSWER: C

Rationale:

This patient has life-threatening hyperkalemia with ECG changes requiring immediate cardiac membrane stabilization — the primary purpose of calcium gluconate. The digoxin interaction is real: digoxin inhibits Na/K-ATPase, raises intracellular sodium, reduces sodium-calcium exchanger (NCX) activity, and elevates intracellular calcium; exogenous calcium compounds this intracellular calcium burden and increases triggered arrhythmia risk. However, calcium gluconate is not absolutely contraindicated in this setting. The risk of withholding membrane stabilization in a patient with K 7.0 mEq/L and ECG changes — imminent ventricular fibrillation — far exceeds the digoxin interaction risk. The correct modification is slow infusion over 20–30 minutes rather than a rapid bolus, which attenuates the peak intracellular calcium surge while still achieving membrane stabilization. Insulin with dextrose follows as the redistribution agent (Na/K-ATPase stimulation in skeletal muscle, onset 15–30 minutes, duration 4–6 hours). SZC is the appropriate definitive elimination agent: with approximately 1-hour onset and approval for acute hyperkalemia, it is preferred over patiromer (4–24 hour onset) in this setting. Hemodialysis would be required if urine output is absent.

Option A: Option A is incorrect: withholding calcium gluconate entirely in a patient with K 7.0 mEq/L and ECG changes risks immediate ventricular fibrillation; insulin alone cannot stabilize the cardiac membrane and its 15–30 minute onset creates an unacceptable window of arrhythmia vulnerability; the digoxin interaction risk is real but does not outweigh imminent cardiac arrest risk.
Option B: Option B is incorrect: sodium bicarbonate is a weak potassium-lowering agent with limited efficacy in the absence of severe acidemia; it generates CO₂ that worsens intracellular acidosis and does not stabilize the cardiac membrane as effectively as calcium; it is not the correct first intervention in this scenario.
Option D: Option D is incorrect: calcium chloride requires central venous access due to severe tissue necrosis risk if extravasated peripherally; choosing calcium chloride for a peripheral IV in this patient is potentially harmful; the mechanism cited — lower pH reducing intracellular calcium loading — is pharmacologically fabricated and not a valid reason to prefer calcium chloride in digoxin-treated patients.
Option E: Option E is incorrect: a rapid 2 g bolus of calcium gluconate in a therapeutic-range digoxin patient maximizes the risk of triggered ventricular arrhythmias from intracellular calcium overload; the modification specifically required is slow infusion, not bolus administration; insulin should not be withheld — hypoglycemia risk is managed by dextrose co-administration, and insulin remains the most effective redistribution agent.

2. A 64-year-old woman with major depressive disorder on sertraline for 8 months presents to her primary care physician with fatigue, mild nausea, and serum sodium of 126 mEq/L. She is euvolemic on examination. Urine sodium is 48 mEq/L, urine osmolality is 510 mOsm/kg, and serum osmolality is 265 mOsm/kg. She is alert and oriented with no neurological symptoms. Her physician diagnoses SSRI-associated SIADH. Which of the following represents the most appropriate initial pharmacological management strategy for this stable, asymptomatic patient?

A) Initiate fluid restriction to 800–1000 mL total daily fluid intake as the first-line intervention; isotonic saline is contraindicated because ongoing autonomous ADH activity will cause excreted concentrated urine to retain the water fraction, paradoxically worsening hyponatremia; if fluid restriction fails after several days, urea 15–30 g/day orally is an appropriate next step that corrects hyponatremia osmotically without the unpredictable correction risks of vaptans
B) Administer isotonic 0.9% saline at 125 mL/hour to restore serum sodium toward 135 mEq/L; the patient's euvolemic state indicates sodium depletion that must be repleted; urine sodium of 48 mEq/L confirms ongoing renal sodium wasting that saline will correct
C) Initiate tolvaptan 15 mg orally immediately in the outpatient setting given that fluid restriction is inconvenient and unreliable in the ambulatory setting; tolvaptan's aquaretic mechanism is ideal for SIADH and can be titrated to a correction rate of 10–15 mEq/L per 24 hours to rapidly normalize sodium
D) Administer 3% hypertonic saline at 1 mL/kg/hour because the serum sodium of 126 mEq/L is below 130 mEq/L and all patients with sodium in this range require urgent pharmacological correction regardless of symptom status
E) Administer demeclocycline 600–1200 mg/day as first-line pharmacological therapy because it induces nephrogenic diabetes insipidus (NDI) by inhibiting ADH-mediated cAMP generation in the collecting duct, directly opposing the SIADH mechanism; demeclocycline is preferred over fluid restriction in outpatients because it requires no behavioral compliance

ANSWER: A

Rationale:

This patient has stable, non-symptomatic SSRI-associated SIADH. The constellation of euvolemia, concentrated urine (osmolality 510 mOsm/kg), elevated urine sodium (48 mEq/L), and low serum osmolality (265 mOsm/kg) confirms autonomous ADH activity. For stable, asymptomatic SIADH, fluid restriction to 800–1000 mL total daily fluid intake is the cornerstone first-line intervention — it reduces free water intake below the rate of urinary water excretion (even though the urine is concentrated), allowing serum sodium to rise gradually and safely. Isotonic saline is specifically contraindicated in SIADH: the sodium in the saline is excreted in highly concentrated urine while the water fraction is retained under persistent ADH drive, paradoxically worsening hyponatremia. If fluid restriction is insufficient after several days, urea (15–30 g/day) is an effective, low-risk oral agent that creates an osmotic gradient promoting free water excretion independent of the ADH axis, without the unpredictable correction rates of vaptans that require inpatient monitoring. Consideration should also be given to reducing or discontinuing sertraline if clinically feasible.

Option B: Option B is incorrect: isotonic saline is contraindicated in SIADH; the urine sodium of 48 mEq/L reflects autonomous ADH-driven sodium handling, not sodium depletion; administering saline will result in the sodium being excreted in concentrated urine while the water is retained, worsening the hyponatremia.
Option C: Option C is incorrect: tolvaptan must be initiated in a monitored inpatient setting due to unpredictable sodium correction rates risking osmotic demyelination syndrome; outpatient initiation is not acceptable; targeting 10–15 mEq/L per 24 hours substantially exceeds the safe correction limit of 6–8 mEq/L per 24 hours.
Option D: Option D is incorrect: 3% hypertonic saline is reserved for acute severe hyponatremia with neurological symptoms (seizures, obtundation, herniation signs); this patient is asymptomatic and alert; using hypertonic saline in a neurologically intact patient with sodium of 126 mEq/L risks dangerous overcorrection and ODS.
Option E: Option E is incorrect: demeclocycline was historically used for chronic SIADH but is no longer first-line and has been largely supplanted by fluid restriction, urea, and vaptans; it causes photosensitivity, nephrotoxicity, and its onset takes days to weeks; it is not appropriate before fluid restriction has been attempted in a stable outpatient.

3. A 47-year-old man with alcohol use disorder and malnutrition is admitted with confusion and serum sodium of 112 mEq/L. His family reports he has been symptomatic for at least 4 days. Three percent hypertonic saline is initiated at 1 mL/kg/hour. Eight hours later, his repeat sodium is 121 mEq/L — a rise of 9 mEq/L. He is now neurologically improved and conversational. The admitting resident asks whether the infusion should continue at the same rate to complete the correction. Which of the following represents the correct next step in management and best explains the pharmacological rationale?

A) Continue the 3% saline at the current rate; a rise of 9 mEq/L over 8 hours is acceptable because the 24-hour limit of 12 mEq/L has not yet been reached, and completing the correction to 130 mEq/L within 24 hours will eliminate the risk of re-encephalopathy
B) Increase the 3% saline rate because the neurological improvement confirms that the correction is beneficial; targeting a final sodium of 135 mEq/L within 24 hours is appropriate given the severity of the initial hyponatremia
C) Switch from 3% saline to isotonic saline to slow the rate; no pharmacological intervention is needed to reverse the correction already achieved, as the sodium rise will plateau spontaneously once the hypertonic saline is removed
D) Reduce the 3% saline to 0.5 mL/kg/hour and add oral salt tablets to maintain a slow upward trajectory; the 9 mEq/L rise in 8 hours is slightly above the preferred rate but does not require active re-lowering of sodium
E) Stop the 3% saline immediately; the 9 mEq/L rise in 8 hours — projected to approximately 27 mEq/L over 24 hours — already exceeds the safe correction ceiling of 6–8 mEq/L per 24 hours; administer desmopressin to clamp further free water excretion and give free water as D5W IV or orally to actively re-lower the sodium back toward the safe correction zone, because this patient's profile — alcoholism, malnutrition, chronic severe hyponatremia (at least 4 days), and serum sodium below 115 mEq/L — places him at the highest risk for osmotic demyelination syndrome

ANSWER: E

Rationale:

The safe correction ceiling for chronic hyponatremia is 6–8 mEq/L in the first 24 hours (absolute maximum 10–12 mEq/L in any 24-hour period). This patient's sodium has risen 9 mEq/L in only 8 hours. At the current rate, the 24-hour projected rise is approximately 27 mEq/L — catastrophically above the safe limit. The neurological improvement is welcome but does not authorize continued rapid correction; ODS can develop despite clinical improvement if the sodium continues to rise rapidly. The immediate rescue protocol is: (1) stop the hypertonic saline; (2) administer desmopressin (DDAVP), which activates V2 receptors in the collecting duct and drives AQP2-mediated water retention, clamping further free water excretion and halting additional sodium rise; (3) give free water (D5W IV or oral water) to actively re-lower the sodium back into the safe correction zone. This patient combines every major ODS risk factor: serum sodium below 115 mEq/L at baseline, chronic hyponatremia of at least 4 days (confirming full cerebral osmolyte depletion via myoinositol, taurine, and glutamine extrusion), alcoholism, and malnutrition — all independently associated with impaired osmolyte regeneration and catastrophic ODS susceptibility.

Option A: Option A is incorrect: the 9 mEq/L rise occurred in 8 hours, not 24 hours; continuing at this pace would project to approximately 27 mEq/L in 24 hours, far exceeding the 12 mEq/L absolute ceiling; the strategy of completing correction to 130 mEq/L risks devastating irreversible neurological injury.
Option B: Option B is incorrect: neurological improvement does not justify accelerating correction; ODS is caused by rapid sodium rise in chronically adapted brains regardless of symptomatic improvement; targeting 135 mEq/L within 24 hours from a baseline of 112 mEq/L would require a 23 mEq/L rise — nearly four times the safe limit.
Option C: Option C is incorrect: simply switching to isotonic saline does not reverse the overcorrection already achieved; isotonic saline may continue to raise sodium in some clinical contexts and will not actively re-lower it; active rescue with desmopressin and free water is required, not passive deceleration.
Option D: Option D is incorrect: reducing the infusion rate to 0.5 mL/kg/hour continues to raise sodium, does not reverse the already-excessive rise, and adding oral salt tablets would further increase the sodium load; the 9 mEq/L rise in 8 hours does require active re-lowering, not a slower continuation of upward correction.

4. A 58-year-old man is in the surgical ICU following a small bowel obstruction requiring nasogastric decompression for 5 days. He has had persistent nausea and vomiting. Current labs: serum pH 7.54, HCO₃⁻ 38 mEq/L, serum K⁺ 2.9 mEq/L, serum Na⁺ 138 mEq/L, serum Cl⁻ 88 mEq/L. Urine chloride is 6 mEq/L. He is clinically hypovolemic with dry mucous membranes. A medical student suggests starting acetazolamide to correct the alkalosis by forcing urinary bicarbonate excretion. Which of the following best describes the correct treatment for this patient and explains why the student's suggestion, while pharmacologically logical, is inappropriate in this specific context?

A) The student's suggestion is correct; acetazolamide is the first-line treatment for all metabolic alkaloses regardless of etiology because its mechanism of carbonic anhydrase inhibition in the proximal tubule is universally applicable; isotonic saline should be avoided because it would worsen the alkalosis by adding sodium that drives proximal bicarbonate reabsorption
B) This patient has chloride-responsive metabolic alkalosis (urine Cl below 20 mEq/L) driven by HCl loss from nasogastric suction and vomiting with secondary volume and chloride depletion; the correct treatment is isotonic saline to restore volume and chloride plus potassium chloride to correct hypokalemia — these remove all three sustaining stimuli; acetazolamide is reserved for chloride-resistant metabolic alkalosis in volume-overloaded patients who cannot receive saline, and is contraindicated here because this hypovolemic patient requires volume and chloride repletion, not further urinary bicarbonate wasting
C) This patient requires acetazolamide plus loop diuretic therapy; the loop diuretic will increase chloride delivery to the collecting duct, restoring the chloride gradient for bicarbonate secretion, while acetazolamide forces proximal bicarbonate wasting; potassium chloride is added for hypokalemia but saline should be avoided
D) This patient has chloride-resistant metabolic alkalosis because his urine chloride is below 20 mEq/L; treatment requires spironolactone to block aldosterone-driven hydrogen ion secretion in the collecting duct; isotonic saline is not indicated because volume expansion without aldosterone blockade will not break the cycle of bicarbonate reabsorption
E) This patient's metabolic alkalosis is self-limiting once nasogastric suction is discontinued; no pharmacological intervention is required; potassium chloride alone is sufficient to correct the alkalosis because hypokalemia is the only sustaining mechanism, and once potassium is normalized the collecting duct will cease hydrogen ion secretion and allow bicarbonate to be excreted spontaneously

ANSWER: B

Rationale:

The urine chloride of 6 mEq/L — below 20 mEq/L — definitively classifies this as chloride-responsive metabolic alkalosis. The mechanism is HCl loss from nasogastric suction and vomiting, which depletes chloride and volume simultaneously and triggers secondary hyperaldosteronism from RAAS activation. Three interlocking mechanisms sustain the alkalosis: (1) chloride depletion impairs the collecting duct chloride-bicarbonate exchanger, reducing bicarbonate secretion; (2) volume depletion-driven RAAS activation increases aldosterone, which drives collecting duct H⁺ secretion and perpetuates bicarbonate reabsorption; (3) hypokalemia causes cells to secrete H⁺ to conserve K⁺ intracellularly, further generating bicarbonate. Isotonic saline restores volume (suppressing RAAS) and repletes chloride (restoring the anion gradient for bicarbonate secretion). KCl repletes potassium and provides additional chloride. Together these remove all three sustaining stimuli. Acetazolamide — correct for chloride-resistant alkalosis in volume-overloaded patients such as those with decompensated heart failure — is inappropriate here: this patient is already hypovolemic, and acetazolamide would force further urinary losses including bicarbonate, sodium, potassium, and water, worsening volume depletion and hypokalemia without addressing the root mechanism.

Option A: Option A is incorrect: acetazolamide is not universally first-line for all metabolic alkalosis; it is specifically indicated for chloride-resistant alkalosis in volume-overloaded patients who cannot receive saline; using it in a hypovolemic patient with chloride-responsive alkalosis would exacerbate volume depletion and hypokalemia; isotonic saline does not worsen alkalosis — it is the correct treatment for this patient.
Option C: Option C is incorrect: loop diuretics increase chloride delivery to the thick ascending limb but do not directly restore the chloride-bicarbonate exchanger in the collecting duct; adding a loop diuretic to an already hypovolemic patient would cause dangerous further volume depletion; acetazolamide is not appropriate in this context.
Option D: Option D is incorrect: urine chloride below 20 mEq/L defines chloride-responsive (not chloride-resistant) alkalosis; chloride-resistant alkalosis has urine chloride above 20 mEq/L and is the context where aldosterone blockade with spironolactone is appropriate; misclassifying this patient leads to the wrong treatment entirely.
Option E: Option E is incorrect: while stopping nasogastric suction is essential and part of the overall management, the alkalosis is not purely self-limiting — the chloride and volume deficit require active repletion to remove the RAAS-driven sustaining mechanism; potassium chloride alone is insufficient because volume depletion-driven secondary hyperaldosteronism will continue to drive bicarbonate reabsorption regardless of potassium status.

5. A 22-year-old woman with type 1 diabetes presents to the emergency department with nausea, vomiting, and abdominal pain. Arterial blood gas: pH 7.10, PaCO₂ 18 mmHg, HCO₃⁻ 6 mEq/L. Serum electrolytes: Na⁺ 136 mEq/L, Cl⁻ 102 mEq/L, K⁺ 5.2 mEq/L, glucose 480 mg/dL. She is alert. The anion gap is 28 mEq/L. The attending proposes adding sodium bicarbonate 100 mEq IV to the treatment regimen. A senior resident argues against it. Which of the following best supports the resident's position and identifies the correct treatment?

A) The resident is correct to object; sodium bicarbonate is contraindicated in DKA because it raises serum potassium by driving potassium out of cells in exchange for hydrogen ions, worsening the already-elevated potassium of 5.2 mEq/L and increasing arrhythmia risk; the correct treatment is insulin infusion plus isotonic saline without any alkali supplementation
B) The resident is correct to object; sodium bicarbonate should not be used in DKA because it directly inhibits insulin receptor signaling by raising intracellular pH in adipocytes, promoting continued lipolysis and ketogenesis; the correct treatment is high-dose insulin plus isotonic saline plus phosphate supplementation
C) The resident is correct to object; sodium bicarbonate is contraindicated whenever the serum potassium exceeds 5.0 mEq/L regardless of the underlying acid-base diagnosis; the correct treatment is insulin infusion with potassium monitoring and no bicarbonate until potassium falls below 3.5 mEq/L
D) The resident is correct to object; bicarbonate in DKA generates CO₂ from the buffering reaction that crosses the blood-brain barrier faster than bicarbonate, transiently worsening CSF acidosis (paradoxical CNS acidosis) even as arterial pH rises; additional risks include sodium loading causing hypernatremia and overshoot metabolic alkalosis if ketoacidosis resolves while infusion continues; the correct treatment is insulin infusion plus isotonic saline, which will metabolize ketoacids and regenerate bicarbonate endogenously without these risks
E) The resident is correct to object; sodium bicarbonate should be reserved for patients with pH below 6.9 only; since this patient's pH of 7.10 is above that threshold, bicarbonate is inappropriate; the correct treatment is insulin plus isotonic saline, and bicarbonate should be held until pH drops further

ANSWER: D

Rationale:

The resident's objection is pharmacologically sound. In DKA, the appropriate treatment is insulin (to halt ketogenesis and allow ketoacid metabolism) plus isotonic saline (for volume repletion and to restore renal perfusion for ketoacid excretion). As ketoacids are metabolized, bicarbonate is regenerated endogenously — the kidneys and liver regenerate approximately 1 mEq of HCO₃⁻ for each mEq of ketoacid metabolized. IV bicarbonate adds three independent risks: (1) paradoxical CNS acidosis — the buffering reaction HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O generates CO₂, which crosses the BBB rapidly (lipophilic, uncharged) while bicarbonate crosses slowly; within the CSF, CO₂ regenerates H⁺, lowering CSF pH even as arterial pH rises; this is particularly dangerous in DKA where compensatory hyperventilation (PaCO₂ 18 mmHg here) has already maximally reduced CO₂ buffering reserve; (2) sodium loading from the bicarbonate formulation (1 mEq Na⁺ per mL) risking hypernatremia in a patient already receiving saline; (3) overshoot metabolic alkalosis if the underlying ketoacidosis resolves while bicarbonate continues to infuse. Current consensus guidelines (ADA) do not recommend bicarbonate for DKA unless pH is below 6.9 and even then only with careful monitoring.

Option A: Option A is incorrect: while it is true that bicarbonate drives potassium into cells (which could actually lower the elevated potassium in this patient), this is not the primary reason bicarbonate is avoided in DKA; the key mechanisms against use are paradoxical CNS acidosis, sodium loading, and overshoot alkalosis — not potassium concerns; the correct treatment identification (insulin + saline) is right but the stated reasoning is wrong.
Option B: Option B is incorrect: sodium bicarbonate does not inhibit insulin receptor signaling in adipocytes and does not directly promote lipolysis through intracellular pH changes; this mechanism is fabricated; phosphate supplementation is not a primary component of standard DKA treatment in the absence of severe hypophosphatemia.
Option C: Option C is incorrect: bicarbonate is not contraindicated simply because potassium exceeds 5.0 mEq/L regardless of context; the contraindication in DKA is mechanistic (CO₂ generation, paradoxical CNS acidosis, sodium load) and applies regardless of potassium level; the threshold-based rule stated is not pharmacological standard of care.
Option E: Option E is incorrect: while current guidelines do suggest considering bicarbonate only for pH below 6.9 in DKA, this option states this as the sole reason without explaining the pharmacological mechanisms that make bicarbonate harmful in DKA generally; more importantly, withholding bicarbonate until pH "drops further" is not a management strategy — the goal is insulin-driven resolution of ketoacidosis, not waiting for further deterioration.

6. A 54-year-old man with a renal transplant on tacrolimus develops serum potassium of 5.8 mEq/L and serum HCO₃⁻ of 19 mEq/L on routine labs. His eGFR is 44 mL/min/1.73m². He has no ECG changes and is asymptomatic. Urinalysis shows urine pH of 5.2. Serum aldosterone is low-normal and plasma renin activity is suppressed. The transplant nephrologist identifies a type 4 RTA pattern. Which of the following best explains the mechanism of this presentation and the correct pharmacological management sequence?

A) Tacrolimus, a calcineurin inhibitor (CNI), reduces aldosterone responsiveness in the collecting duct and suppresses ENaC activity, impairing potassium secretion via ROMK and hydrogen ion secretion by intercalated cells, producing the hyperkalemia-plus-mild-NAGMA pattern of type 4 RTA; management prioritizes potassium reduction first (dietary restriction, loop diuretic if appropriate, patiromer or SZC if persistent), with oral sodium bicarbonate added if serum HCO₃⁻ falls below 22 mEq/L
B) Tacrolimus causes type 4 RTA by inhibiting the H⁺/K⁺-ATPase in collecting duct alpha-intercalated cells, directly blocking both proton secretion and potassium reabsorption; the urine pH of 5.2 confirms that distal H⁺ secretion is completely abolished; management requires high-dose sodium bicarbonate at 5–15 mEq/kg/day to overcome the transporter blockade, with fludrocortisone to upregulate ENaC
C) This patient has type 1 distal RTA from tacrolimus nephrotoxicity; the urine pH of 5.2 would be expected to be above 5.5, confirming collecting duct H⁺ secretion failure; management requires 1–2 mEq/kg/day of oral bicarbonate and potassium citrate to prevent nephrolithiasis
D) The suppressed renin and low-normal aldosterone confirm primary adrenal insufficiency from tacrolimus-induced adrenocortical toxicity; the correct management is fludrocortisone replacement at 0.1 mg/day to restore mineralocorticoid activity, which will simultaneously correct both the hyperkalemia and the metabolic acidosis
E) Tacrolimus causes type 4 RTA through direct inhibition of the Na-K-2Cl cotransporter in the thick ascending limb, reducing the lumen-positive potential that drives passive potassium reabsorption; management requires loop diuretics at high doses to compensate for the reduced thick ascending limb transport by increasing flow-mediated distal potassium secretion

ANSWER: A

Rationale:

Calcineurin inhibitors (tacrolimus, cyclosporine) produce a type 4 RTA (hyperkalemic, hyporenin-hypoaldosteronism) pattern through two convergent mechanisms: (1) they reduce aldosterone responsiveness in the collecting duct principal cells, impairing ENaC-mediated sodium reabsorption — the electronegativity that normally drives ROMK-mediated potassium secretion is reduced; (2) they downregulate TRPM6 in the DCT, causing concurrent hypomagnesemia in many patients. The net result is impaired renal potassium excretion (hyperkalemia) and mildly impaired collecting duct H⁺ secretion (non-anion gap metabolic acidosis). Critically, the urine pH of 5.2 in this patient confirms that the collecting duct retains some capacity for H⁺ secretion — urine pH can still fall below 5.5, which excludes type 1 distal RTA (where urine pH cannot fall below 5.5). Type 4 RTA produces only mild acidosis because H⁺ secretion is reduced but not abolished. Management sequence: potassium normalization is the priority (dietary potassium restriction, dose optimization of tacrolimus if feasible, loop diuretic if volume status permits, SZC or patiromer for persistent hyperkalemia); sodium bicarbonate is added when serum HCO₃⁻ falls below 22 mEq/L per KDIGO guidelines.

Option B: Option B is incorrect: tacrolimus does not inhibit H⁺/K⁺-ATPase directly; its mechanism is reduction of aldosterone responsiveness and ENaC suppression in the collecting duct; the urine pH of 5.2 below 5.5 confirms that H⁺ secretion is not completely abolished — which actually distinguishes type 4 from type 1 RTA; the bicarbonate dose of 5–15 mEq/kg/day is for type 2 proximal RTA, not type 4.
Option C: Option C is incorrect: this patient has type 4 RTA, not type 1 distal RTA; urine pH of 5.2 is below 5.5, which excludes type 1 (where urine pH cannot fall below 5.5 despite acidemia); the option misidentifies the RTA type based on a misread of the urine pH finding.
Option D: Option D is incorrect: the suppressed renin and low-normal aldosterone reflect the CNI-induced hyporenin-hypoaldosteronism pattern of type 4 RTA, not primary adrenal insufficiency; tacrolimus does not cause adrenocortical toxicity as its primary mechanism of RTA; fludrocortisone is not the standard treatment for CNI-induced type 4 RTA.
Option E: Option E is incorrect: tacrolimus does not inhibit the Na-K-2Cl cotransporter in the thick ascending limb; NKCC2 inhibition is the mechanism of loop diuretics; loop diuretics at high doses would worsen volume depletion and are not the primary treatment for type 4 RTA from CNI nephrotoxicity.

7. A 61-year-old man with metastatic bladder cancer completed his fourth cycle of cisplatin 6 weeks ago. He presents to oncology clinic with fatigue and muscle cramps. His serum creatinine is 0.9 mg/dL. Labs show serum potassium 2.8 mEq/L and serum magnesium 0.5 mg/dL. His primary care physician has been supplementing with oral potassium chloride 80 mEq/day for the past 3 weeks with no improvement in serum potassium. The oncologist is not surprised. Which of the following best identifies the mechanistic reason why oral potassium replacement has failed and prescribes the correct management?

A) The oral potassium is failing because cisplatin causes permanent aldosterone receptor upregulation in the collecting duct, creating ongoing mineralocorticoid-driven potassium wasting that cannot be overcome by supplementation alone; the correct management is spironolactone to block the upregulated aldosterone receptor, followed by potassium repletion once urinary wasting is controlled
B) The oral potassium is failing because cisplatin has caused a type 2 proximal RTA that wastes potassium along with bicarbonate in the proximal tubule; supplemented potassium is lost in the urine before it can be retained; the correct management is high-dose sodium bicarbonate at 5 mEq/kg/day to alkalinize the tubular fluid and reduce the electrochemical driving force for potassium secretion
C) Cisplatin damaged TRPM6 channels in the distal convoluted tubule, causing persistent urinary magnesium wasting and depleting intracellular magnesium; without Mg²⁺ blocking ROMK from the cytoplasmic side, ROMK remains constitutively open and continuously secretes potassium into the collecting duct lumen regardless of systemic potassium status, making potassium replacement ineffective until magnesium is aggressively repleted; the correct first step is IV magnesium sulfate 1–2 g over 30–60 minutes repeated as needed, followed by continued potassium supplementation once magnesium is repleted
D) The oral potassium is failing because intestinal absorption of potassium is permanently impaired by cisplatin-induced enteropathy affecting potassium absorption channels in the small bowel mucosa; the correct management is to switch from oral to IV potassium chloride at 20 mEq/hour via central access, bypassing the damaged intestinal absorption mechanism
E) The oral potassium is failing because cisplatin has induced SIADH, expanding total body water and diluting serum potassium despite adequate total body potassium stores; the correct management is fluid restriction to 1000 mL/day, which will concentrate serum potassium back to normal levels without additional supplementation

ANSWER: C

Rationale:

Cisplatin's nephrotoxicity preferentially damages the TRPM6 (transient receptor potential melastatin 6) channel in the distal convoluted tubule — the primary apical entry pathway for magnesium reabsorption. Cisplatin-induced tubular injury reduces TRPM6 expression, causing persistent urinary magnesium wasting that continues long after chemotherapy completion and after serum creatinine normalizes, as confirmed here (creatinine 0.9 mg/dL, cisplatin completed 6 weeks ago). The critical downstream consequence is the magnesium-potassium interdependence: intracellular Mg²⁺ normally occupies a blocking site within the ROMK channel pore from the cytoplasmic face, providing voltage-dependent inhibition of potassium secretion into the collecting duct lumen. When intracellular magnesium is depleted by hypomagnesemia, ROMK loses its cytoplasmic block and remains constitutively open — continuously secreting potassium regardless of systemic potassium levels. Every milliequivalent of supplemented potassium (oral or IV) is immediately secreted through constitutively open ROMK channels. The correct management sequence is mandatory: aggressive IV magnesium sulfate repletion first (restoring intracellular Mg²⁺ and re-establishing ROMK blockade), after which potassium supplementation becomes effective and serum potassium can be corrected.

Option A: Option A is incorrect: cisplatin does not upregulate aldosterone receptors in the collecting duct; its mechanism of electrolyte toxicity is renal tubular (TRPM6 channel damage), not adrenal or receptor-level; spironolactone would reduce potassium secretion somewhat but does not address the root cause of ROMK constitutive opening from magnesium depletion, and without magnesium repletion, potassium replacement will still fail.
Option B: Option B is incorrect: cisplatin-induced Fanconi syndrome can include proximal tubular bicarbonate wasting (type 2 RTA pattern), but this is a separate manifestation; the primary cause of refractory hypokalemia in this scenario is the TRPM6/ROMK/magnesium mechanism, not proximal potassium wasting; sodium bicarbonate would not correct the ROMK-mediated renal potassium secretion.
Option D: Option D is incorrect: cisplatin does not cause permanent intestinal potassium absorption channel damage; its renal toxicity is the mechanism of hypokalemia; switching to IV potassium will have the same result as oral — potassium will be continuously secreted through open ROMK channels as long as hypomagnesemia persists; the route of supplementation is not the limiting factor.
Option E: Option E is incorrect: cisplatin-induced SIADH is not the established mechanism of persistent post-chemotherapy hypokalemia; SIADH would cause hyponatremia with dilutional hypokalemia, but this patient's sodium is not reported as low, and the serum magnesium of 0.5 mg/dL points directly to the TRPM6 tubular toxicity mechanism; fluid restriction would not correct the ROMK-mediated renal potassium wasting.

8. A 52-year-old woman with bipolar I disorder on lithium 900 mg/day for 10 years develops polyuria of 7 liters per day consistent with nephrogenic diabetes insipidus (NDI). She also has CKD stage 3a (eGFR 52 mL/min/1.73m²) and serum potassium of 5.3 mEq/L. Her psychiatrist wishes to reduce the polyuria pharmacologically. Amiloride is considered but the nephrologist advises against it. Which of the following best identifies why amiloride is relatively contraindicated in this patient, selects the correct alternative, and identifies the mandatory monitoring required with that alternative?

A) Amiloride is contraindicated because it inhibits carbonic anhydrase in the proximal tubule, worsening the bicarbonate wasting that is already accelerated by CKD; the correct alternative is indomethacin, a non-selective COX inhibitor that reduces prostaglandin-mediated aquaporin-2 downregulation; monitoring required is serum creatinine every 2 weeks
B) Amiloride is contraindicated because CKD reduces its renal clearance, causing amiloride to accumulate and inhibit Na/K-ATPase systemically, risking cardiac arrhythmias; the correct alternative is desmopressin, which partially overcomes the collecting duct adenylate cyclase inhibition by lithium at supraphysiological doses; monitoring required is serum sodium every 48 hours
C) Amiloride is contraindicated because at CKD stage 3a its renal elimination is sufficiently impaired that drug accumulates to supratherapeutic levels, making ENaC blockade irreversible rather than competitive; the correct alternative is low-dose furosemide, which reduces collecting duct lithium delivery by increasing urinary flow rate and diluting tubular lithium concentration; monitoring required is serum creatinine given furosemide's volume-depleting effect on renal perfusion
D) Amiloride is contraindicated because it competes with lithium for ENaC binding sites and paradoxically increases intracellular lithium accumulation in collecting duct principal cells, worsening the adenylate cyclase inhibition and the NDI; the correct alternative is furosemide, which delivers more sodium to the distal nephron, diluting intracellular lithium by competing for ENaC entry
E) Amiloride is relatively contraindicated in this patient because it blocks ENaC in the collecting duct, reducing potassium secretion via ROMK; with existing hyperkalemia at 5.3 mEq/L and CKD stage 3a already impairing renal potassium handling, amiloride risks clinically significant hyperkalemia; the correct alternative is a thiazide diuretic, which paradoxically reduces polyuria through volume contraction-driven proximal tubular reabsorption of sodium and lithium, reducing lithium delivery to collecting duct principal cells and attenuating adenylate cyclase inhibition; the mandatory monitoring is serum lithium levels, because the same proximal reabsorption mechanism that reduces collecting duct lithium also raises serum lithium concentration, risking toxicity and necessitating lithium dose reduction

ANSWER: E

Rationale:

Amiloride is the standard first-line agent for lithium-induced NDI: it blocks ENaC on the apical membrane of collecting duct principal cells, reducing lithium uptake into the cell, thereby attenuating adenylate cyclase inhibition and partially restoring cAMP-driven AQP2 insertion. However, ENaC blockade also reduces the electronegativity of the collecting duct lumen that drives ROMK-mediated potassium secretion. In a patient with CKD (already impairing renal potassium excretion) and existing hyperkalemia at 5.3 mEq/L, adding amiloride risks clinically significant or life-threatening hyperkalemia. The thiazide alternative works through a completely different mechanism — paradoxical polyuria reduction via volume contraction: thiazides inhibit NCC (Na-Cl cotransporter) in the DCT, causing urinary sodium loss and volume contraction, which triggers compensatory proximal tubular sodium and lithium reabsorption. Reduced lithium delivery to the collecting duct attenuates intracellular lithium accumulation and adenylate cyclase inhibition, partially restoring AQP2 responsiveness. The critical safety consequence: the same proximal reabsorption that reduces collecting duct lithium also reduces urinary lithium clearance and raises serum lithium levels. Lithium toxicity — with its narrow therapeutic index — is a real risk. Serum lithium must be monitored closely and the lithium dose reduced proportionally.

Option A: Option A is incorrect: amiloride does not inhibit carbonic anhydrase; it blocks ENaC; carbonic anhydrase inhibition is the mechanism of acetazolamide; indomethacin is occasionally used as an adjunct in NDI but is not the standard alternative when amiloride is contraindicated by hyperkalemia; NSAIDs are nephrotoxic and would worsen CKD.
Option B: Option B is incorrect: amiloride is not contraindicated due to Na/K-ATPase inhibition; amiloride does not inhibit Na/K-ATPase; Na/K-ATPase inhibition is the mechanism of digoxin; desmopressin cannot overcome lithium-induced NDI even at supraphysiological doses because the defect is intracellular (adenylate cyclase inhibition), not at the V2 receptor.
Option C: Option C is incorrect: amiloride's ENaC blockade is competitive and reversible regardless of CKD stage 3a — accumulation does not convert it to irreversible inhibition; furosemide does not reduce collecting duct lithium delivery by diluting tubular lithium concentration; furosemide causes volume depletion, which paradoxically increases proximal lithium reabsorption and raises serum lithium — the opposite of what this option claims — and worsening CKD with a loop diuretic in this context is an additional risk.
Option D: Option D is incorrect: amiloride does not compete with lithium for ENaC binding sites in a way that increases intracellular lithium accumulation — it blocks ENaC to reduce lithium entry; furosemide delivers more sodium to the distal nephron and does not reduce intracellular lithium; furosemide causes volume depletion and would worsen CKD.

9. A 28-year-old woman with acute myeloid leukemia post-induction chemotherapy develops invasive pulmonary aspergillosis. She is started on conventional amphotericin B deoxycholate. After 12 days, her serum creatinine has risen from 0.8 to 2.1 mg/dL, serum potassium is 2.6 mEq/L requiring 120 mEq IV replacement daily to maintain, serum magnesium is 0.6 mg/dL, and urine pH is 6.0 despite venous pH of 7.28 and HCO₃⁻ of 17 mEq/L. The treatment team asks whether to continue conventional amphotericin B or switch formulations. Which of the following best identifies the mechanism producing this electrolyte pattern and the correct management decision?

A) The electrolyte abnormalities represent expected dose-dependent cisplatin nephrotoxicity from concurrent chemotherapy rather than amphotericin B toxicity; conventional amphotericin B should be continued since it is not the culprit; the TRPM6 mechanism from cisplatin is causing the hypomagnesemia and ROMK-mediated refractory hypokalemia
B) Conventional amphotericin B has inserted into mammalian renal tubular cell membranes at cholesterol-rich sites in the distal tubule and collecting duct, forming pores that increase membrane permeability to potassium and hydrogen ions — causing urinary potassium wasting, impaired H⁺ secretion producing the type 1 distal RTA pattern (urine pH 6.0 that cannot fall below 5.5 despite systemic acidemia), and hypomagnesemia from disrupted magnesium reabsorption; this nephrotoxicity pattern at day 12 with rising creatinine is the established clinical threshold for switching to liposomal amphotericin B, which delivers the same antifungal pore-forming mechanism to ergosterol-rich fungal membranes while limiting free drug exposure to mammalian tubular cells
C) The urine pH of 6.0 in the setting of systemic acidemia confirms a type 2 proximal RTA from amphotericin B impairing bicarbonate reabsorption in the PCT; conventional amphotericin B should be continued because the proximal RTA pattern is self-limiting once the total cumulative dose reaches 2 g; high-dose sodium bicarbonate at 5–15 mEq/kg/day should be started to overcome the proximal bicarbonate wasting
D) The rising creatinine and electrolyte losses represent amphotericin B-induced acute interstitial nephritis rather than tubular toxicity; prednisone 1 mg/kg/day should be started and amphotericin B continued at the same dose; the electrolyte abnormalities will resolve with corticosteroid therapy without requiring a change in antifungal formulation
E) The electrolyte abnormalities are from amphotericin B-induced mineralocorticoid receptor activation, not direct tubular toxicity; fludrocortisone 0.1 mg/day should be added to counteract the excessive mineralocorticoid-driven potassium and hydrogen ion secretion; the conventional formulation can be continued because the mineralocorticoid mechanism is independent of the cholesterol membrane insertion pathway

ANSWER: B

Rationale:

This patient's constellation — rising creatinine, severe refractory hypokalemia, hypomagnesemia, and a urine pH that cannot fall below 5.5 despite systemic acidemia (venous pH 7.28, HCO₃⁻ 17 mEq/L with urine pH 6.0) — is the classic triad of conventional amphotericin B renal tubular toxicity. The mechanism is membrane pore formation: amphotericin B inserts into cholesterol-rich mammalian renal tubular cell membranes in the distal tubule and collecting duct (in addition to its therapeutic insertion into ergosterol-rich fungal membranes), creating ion-conducting pores that allow potassium and hydrogen ions to leak across the tubular cell membrane. Potassium loss causes hypokalemia; impaired H⁺ secretion by collecting duct intercalated cells produces the type 1 distal RTA pattern with inability to lower urine pH below 5.5. Hypomagnesemia follows from disruption of magnesium reabsorption in the distal tubule. The presence of rising creatinine together with these electrolyte manifestations at day 12 represents the established clinical threshold for switching to liposomal amphotericin B, which encapsulates the drug in lipid vesicles that preferentially interact with ergosterol-rich fungal membranes and dramatically limit free drug exposure to mammalian cholesterol-containing tubular cells — preserving antifungal efficacy while substantially reducing tubular toxicity.

Option A: Option A is incorrect: while cisplatin causes TRPM6-mediated hypomagnesemia and ROMK-mediated hypokalemia, the type 1 distal RTA pattern with inability to lower urine pH below 5.5 is specifically produced by amphotericin B membrane pore formation, not cisplatin; cisplatin-induced Fanconi syndrome would produce a proximal (type 2) RTA pattern; post-induction AML chemotherapy does not include cisplatin as a standard agent.
Option C: Option C is incorrect: the urine pH of 6.0 that cannot fall below 5.5 despite systemic acidemia confirms type 1 distal RTA (collecting duct H⁺ secretion impairment), not type 2 proximal RTA; type 2 proximal RTA produces urinary bicarbonate wasting but preserves distal H⁺ secretion and can lower urine pH below 5.5 when plasma bicarbonate falls below the reabsorption threshold; a cumulative dose threshold of 2 g for continuation is not an established clinical standard.
Option D: Option D is incorrect: the pattern of hypokalemia, hypomagnesemia, and non-anion gap acidosis with urine pH above 5.5 is specifically tubular toxicity from amphotericin B membrane pore formation, not acute interstitial nephritis; corticosteroids do not treat amphotericin B tubular toxicity; continuing the same conventional formulation would perpetuate the toxicity.
Option E: Option E is incorrect: amphotericin B does not activate the mineralocorticoid receptor; its renal toxicity is a direct physical consequence of membrane pore insertion into cholesterol-rich tubular cell membranes; fludrocortisone would worsen hypokalemia by increasing aldosterone-driven potassium secretion.

10. A 41-year-old man with HIV on tenofovir disoproxil fumarate (TDF)/emtricitabine/efavirenz for 5 years presents with fatigue and bone pain. Labs: creatinine 1.2 mg/dL (baseline 0.9 mg/dL), HCO₃⁻ 18 mEq/L, serum phosphate 1.9 mg/dL, urine glucose 3+ with fasting blood glucose 86 mg/dL, urine amino acids positive. His HIV viral load is undetectable. The infectious disease physician diagnoses TDF-induced Fanconi syndrome. Which of the following best explains the subcellular mechanism and identifies the correct antiretroviral switch?

A) TDF inhibits SGLT2 in the proximal convoluted tubule, causing glycosuria; the phosphaturia and aminoaciduria result from secondary osmotic tubular injury from the glycosuria overwhelming proximal reabsorptive capacity; the correct switch is to an integrase strand transfer inhibitor (INSTI) class antiretroviral to maintain viral suppression without any nucleotide reverse transcriptase inhibitor
B) TDF causes Fanconi syndrome by forming platinum-DNA adducts in proximal tubular cell nuclei, reducing expression of all PCT transporters simultaneously; the correct switch is to tenofovir alafenamide fumarate (TAF), which is a structural analog of TDF with a modified ring that does not form platinum adducts; TAF must be dose-reduced in CKD stage 3a
C) TDF causes Fanconi syndrome through direct inhibition of the Na/K-ATPase throughout the proximal convoluted tubule, reducing the basolateral sodium gradient required for all secondary active transport of glucose, phosphate, and amino acids; the correct switch is from TDF to abacavir, which inhibits reverse transcriptase without any renal tubular toxicity
D) TDF is actively secreted into PCT cells via OAT1, where it accumulates in mitochondria and inhibits mitochondrial DNA polymerase gamma, causing mitochondrial dysfunction that impairs energy-dependent active transport of glucose, phosphate, amino acids, and bicarbonate — producing the full Fanconi syndrome; the correct switch is to tenofovir alafenamide fumarate (TAF), a prodrug that achieves effective intracellular concentrations in lymphocytes at approximately 90% lower plasma tenofovir-equivalent concentrations, dramatically reducing OAT1-mediated tubular uptake and mitochondrial toxicity while maintaining full antiviral efficacy; TAF does not require dose adjustment for mild-to-moderate CKD
E) TDF causes Fanconi syndrome by activating TLR4 (toll-like receptor 4) on PCT cells, triggering an inflammatory cascade that downregulates expression of SGLT2, NaPi-IIa, and amino acid transporters simultaneously; the correct switch is to TAF plus the addition of mycophenolate mofetil to suppress the TLR4-driven proximal tubular inflammation

ANSWER: D

Rationale:

TDF (tenofovir disoproxil fumarate) undergoes active secretion into proximal convoluted tubule cells via OAT1 (organic anion transporter 1) on the basolateral membrane, where intracellular hydrolysis releases tenofovir. Tenofovir diphosphate, the active metabolite, accumulates in PCT mitochondria and inhibits mitochondrial DNA polymerase gamma — the enzyme responsible for replicating mitochondrial DNA. Mitochondrial dysfunction impairs oxidative phosphorylation in PCT cells, which depend almost entirely on mitochondrial ATP generation for the energy-dependent active transport of all major proximal tubular solutes: glucose (SGLT2, SGLT1), phosphate (NaPi-IIa), amino acids (multiple cotransporters), and bicarbonate (NHE3, NBC1). The simultaneous failure of all these transport processes produces the full Fanconi syndrome — glycosuria despite normoglycemia, phosphaturia causing hypophosphatemia and bone pain, aminoaciduria, and type 2 proximal RTA (HCO₃⁻ 18 mEq/L from urinary bicarbonate wasting). The correct switch is TAF (tenofovir alafenamide fumarate): TAF is a prodrug that undergoes intracellular cleavage to release tenofovir diphosphate directly within target lymphocytes at approximately 90% lower plasma tenofovir concentrations compared with TDF. The dramatically lower plasma levels reduce OAT1-mediated PCT uptake and mitochondrial polymerase gamma inhibition in tubular cells, while intracellular activation in lymphocytes maintains full antiviral potency. TAF does not require dose adjustment for mild-to-moderate CKD.

Option A: Option A is incorrect: TDF does not inhibit SGLT2; SGLT2 inhibition is the mechanism of the SGLT2 inhibitor drug class (empagliflozin, dapagliflozin); TDF's mechanism is mitochondrial DNA polymerase gamma inhibition causing pan-proximal mitochondrial dysfunction; switching to an INSTI without a nucleoside/nucleotide backbone would leave an incomplete antiretroviral regimen unless carefully planned.
Option B: Option B is incorrect: TDF does not form platinum-DNA adducts; that is the mechanism of cisplatin; TDF's toxicity is through the tenofovir diphosphate metabolite inhibiting mitochondrial DNA polymerase gamma; TAF does not have a "modified ring" that prevents platinum adducts — it achieves renal safety through a prodrug mechanism reducing plasma tenofovir levels; TAF does not require dose reduction for mild-to-moderate CKD.
Option C: Option C is incorrect: TDF does not inhibit Na/K-ATPase; Na/K-ATPase inhibition is the mechanism of cardiac glycosides; TDF's mechanism is mitochondrial, not direct pump inhibition; abacavir is a nucleoside reverse transcriptase inhibitor with a different resistance profile and is not a straightforward substitution for tenofovir in all regimens.
Option E: Option E is incorrect: TDF does not activate TLR4 on PCT cells; TLR4 is a pattern recognition receptor for bacterial lipopolysaccharide; the mechanism of TDF nephrotoxicity is mitochondrial, not inflammatory-TLR4-mediated; mycophenolate mofetil is an immunosuppressant and would be inappropriate in an HIV patient requiring antiretroviral therapy optimization.

11. A 78-year-old woman is admitted with decompensated heart failure and 15 kg of fluid overload. Despite IV furosemide 120 mg twice daily for 3 days, her daily urine output has been only 1.2–1.5 liters and her weight is not falling. Her serum bicarbonate is 37 mEq/L, pH 7.52, serum potassium is 3.0 mEq/L, and serum chloride is 89 mEq/L. The cardiologist proposes adding acetazolamide. Which of the following best describes the complete pharmacological management strategy for this patient, including why the metabolic alkalosis is contributing to diuretic resistance and what additional intervention is essential when acetazolamide is added?

A) Acetazolamide inhibits carbonic anhydrase in the proximal convoluted tubule, impairing bicarbonate reabsorption and forcing urinary bicarbonate wasting, which lowers serum bicarbonate and removes the competitive inhibition of furosemide at the Na-K-2Cl cotransporter by tubular bicarbonate, restoring loop diuretic efficacy; however, acetazolamide promotes urinary loss of potassium alongside bicarbonate and sodium, so potassium chloride supplementation must be initiated or intensified concurrently to prevent worsening hypokalemia, which would itself perpetuate the alkalosis through increased collecting duct H⁺ secretion
B) Acetazolamide inhibits aldosterone at the mineralocorticoid receptor in the collecting duct, breaking the cycle of aldosterone-driven H⁺ and K⁺ secretion that sustains the metabolic alkalosis; potassium supplementation is not needed because aldosterone blockade will prevent further urinary potassium losses; the restored collecting duct function simultaneously corrects diuretic resistance by increasing sodium delivery to the loop of Henle
C) Acetazolamide produces aquaresis by blocking V2 vasopressin receptors in the collecting duct, generating electrolyte-free water excretion that dilutes the elevated serum bicarbonate and reduces serum osmolality to improve diuretic responsiveness; potassium supplementation is not required because aquaresis does not cause electrolyte losses
D) Acetazolamide corrects the metabolic alkalosis by stimulating aldosterone secretion from the adrenal cortex, which drives collecting duct H⁺ secretion in exchange for bicarbonate; this aldosterone-driven mechanism also increases ENaC-mediated sodium delivery to the loop of Henle, amplifying furosemide's natriuretic effect; potassium chloride supplementation is avoided because aldosterone-stimulated potassium secretion would be worsened
E) The metabolic alkalosis is not contributing to diuretic resistance in this patient; the correct explanation for inadequate response is furosemide underdosing, and the solution is to double the furosemide dose to 240 mg twice daily; acetazolamide is not indicated because its bicarbonate-wasting mechanism would correct the alkalosis too rapidly and cause osmotic demyelination syndrome

ANSWER: A

Rationale:

Metabolic alkalosis contributes to loop diuretic resistance through a well-characterized tubular mechanism: elevated bicarbonate in the tubular lumen competitively inhibits furosemide's binding to the Na-K-2Cl (NKCC2) cotransporter in the thick ascending limb, reducing the drug's natriuretic and diuretic efficacy. Acetazolamide corrects this by inhibiting carbonic anhydrase (CA) in the proximal convoluted tubule: CA normally catalyzes HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O at the luminal surface, allowing bicarbonate reabsorption. When CA is inhibited, bicarbonate is excreted in the urine, lowering serum bicarbonate without sodium loading — critical in this volume-overloaded patient who cannot receive isotonic saline. The ADVOR trial confirmed this combination improves decongestion in hospitalized heart failure patients. The essential concurrent intervention is potassium chloride supplementation: acetazolamide promotes urinary excretion of sodium, potassium, and bicarbonate together (because bicarbonate acts as an obligate urinary anion that carries cations with it into the urine). This patient already has hypokalemia at 3.0 mEq/L; acetazolamide without potassium replacement will further deplete potassium, which perpetuates the alkalosis — hypokalemia drives collecting duct cells to secrete H⁺ to retain K⁺, continuously regenerating bicarbonate and undermining the correction.

Option B: Option B is incorrect: acetazolamide acts on carbonic anhydrase in the proximal tubule, not on the mineralocorticoid receptor; aldosterone receptor antagonism is the mechanism of spironolactone and eplerenone; acetazolamide does not prevent urinary potassium losses — it worsens them by promoting bicarbonate-driven cation excretion, making potassium supplementation essential, not unnecessary.
Option C: Option C is incorrect: acetazolamide does not block V2 vasopressin receptors; V2 receptor antagonism producing aquaresis is the mechanism of vaptans (tolvaptan, conivaptan); acetazolamide produces bicarbonaturia, not electrolyte-free water excretion; potassium losses occur with acetazolamide and must be replaced.
Option D: Option D is incorrect: acetazolamide does not stimulate aldosterone secretion from the adrenal cortex; its mechanism is direct enzymatic inhibition of carbonic anhydrase in the proximal tubule; increased aldosterone would worsen hypokalemia and perpetuate metabolic alkalosis rather than correcting it.
Option E: Option E is incorrect: the metabolic alkalosis is a well-established contributor to loop diuretic resistance in heart failure through the bicarbonate-NKCC2 competitive inhibition mechanism; simply doubling furosemide without addressing the alkalosis is less effective and carries higher risk of ototoxicity; acetazolamide does not cause osmotic demyelination syndrome — ODS is a specific complication of rapid sodium correction in hyponatremia, not of bicarbonate correction in metabolic alkalosis.